TLR ligands stimulation protects MSC from NK killing

Stem Cells

Volumn 32, Issue 1, 2014, Pages 290-300

  Giuliani, Massimo ^a   Bennaceur Griscelli, Annelise ^b,c,d   Nanbakhsh, Arash ^e   Oudrhiri, Noufissa ^b,c   Chouaib, Salem ^e   Azzarone, Bruno ^f   Durrbach, Antoine ^c,d   Lataillade, Jean Jacques ^a  

^a Military Hospital Percy   (France)

^b Centre National de la Recherche Scientifique   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f G GASLINI INSTITUTE   (Italy)

Author keywords

Immunotolerance; Mesenchymal stem cells; NK cells; NKG2D ligands; TLR

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

ADULT; ARTICLE; CELL INTERACTION; CELL KILLING; CELL PROTECTION; CONTROLLED STUDY; CYTOLYSIS; EMBRYO; FEMALE; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; NATURAL KILLER CELL; PROTEIN FUNCTION;

IMMUNOTOLERANCE; MESENCHYMAL STEM CELLS; NK CELLS; NKG2D LIGANDS; TLR;

FLOW CYTOMETRY; HELA CELLS; HUMANS; K562 CELLS; KILLER CELLS, NATURAL; LIGANDS; MESENCHYMAL STROMAL CELLS; TOLL-LIKE RECEPTORS;

EID: 84891756200     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1563     Document Type: Article

References (46)

1. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-317.
2. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726-736.
3. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versushost disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363: 1439-1441.
4. Le Blanc K, Tammik C, Rosendahl K et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003;31: 890-896.
5. Ringden O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81:1390-1397.
6. Poggi A, Prevosto C, Massaro AM et al. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: Role of NKp30 and NKG2D receptors. J Immunol 2005;175:6352-6360.
7. Spaggiari GM, Capobianco A, Becchetti S et al. Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NKcell proliferation. Blood 2006;107:1484-1490.
8. Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science 2004;306: 1517-1519.
9. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001;1:41-49.
10. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990;11:237-244.
11. Spaggiari GM, Capobianco A, Abdelrazik H et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008;111:1327-1333.
12. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008;27:5944-5958.
13. Crisostomo PR, Wang Y, Markel TA et al. Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an Nf Kappa B-but not JNK-dependent Mechanism. Am J Physiol Cell Physiol 2008;294:C675-682.
14. DelaRosa O, Lombardo E. Modulation of adult mesenchymal stem cells activity by tolllike receptors: Implications on therapeutic potential. Mediators Inflamm 2010;2010: 865601.
15. Liotta F, Angeli R, Cosmi L et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 2008;26:279-289.
16. Raicevic G, Najar M, Stamatopoulos B et al. The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties. Cell Immunol 2011;270:207-216.
17. Romieu-Mourez R, Francois M, Boivin MN et al. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol 2009;182:7963-7973.
18. Waterman RS, Tomchuck SL, Henkle SL et al. A new mesenchymal stem cell (MSC) paradigm: Polarization into a proinflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One 2010;5: e10088.
19. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1: 135-145.
20. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004;16:3-9.
21. Pasare C, Medzhitov R. Toll-like receptors: Linking innate and adaptive immunity. Adv Exp Med Biol 2005;560:11-18.
22. Goldstein DR, Tesar BM, Akira S et al. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003;111:1571-1578.
23. Obhrai J, Goldstein DR. The role of tolllike receptors in solid organ transplantation. Transplantation 2006;81:497-502.
24. van den Berk LC, Jansen BJ, Siebers-Vermeulen KG et al. Toll-like receptor triggering in cord blood mesenchymal stem cells. J Cell Mol Med 2009;13:3415-3426.
25. Opitz CA, Litzenburger UM, Lutz C et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 2009;27:909-919.
26. Kitchens WH, Uehara S, Chase CM et al. The changing role of natural killer cells in solid organ rejection and tolerance. Transplantation 2006;81:811-817.
27. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-2100.
28. Giuliani M, Oudrhiri N, Noman ZM et al. Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood 2011;118: 3254-3262.
29. Trivedi P, Hematti P. Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells. Exp Hematol 2008;36:350-359.
30. Yen BL, Chang CJ, Liu KJ et al. Brief report-Human embryonic stem cell-derived mesenchymal progenitors (EMPs) possess strong immunosuppressive effects towards natural killer cells as well as T lymphocytes. Stem Cells 2009;27:451-456.
31. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999;17:875-904.
32. Moretta A, Bottino C, Vitale M et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197-223.
33. Bauer S, Groh V, Wu J et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285: 727-729.
34. Cosman D, Mullberg J, Sutherland CL et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001;14:123-133.
35. Pende D, Cantoni C, Rivera P et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: Cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001;31:1076-1086.
36. Sutherland CL, Chalupny NJ, Schooley K et al. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 2002;168:671-679.
37. Groh V, Wu J, Yee C et al. Tumourderived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419:734-738.
38. Salih HR, Rammensee HG, Steinle A. Cutting edge: Down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002;169:4098-4102.
39. Eissmann P, Evans JH, Mehrabi M et al. Multiple mechanisms downstream of TLR-4 stimulation allow expression of NKG2D ligands to facilitate macrophage/NK cell crosstalk. J Immunol 2010;184:6901-6909.
40. Hamerman JA, Ogasawara K, Lanier LL. Cutting edge: Toll-like receptor signaling in macrophages induces ligands for the NKG2D receptor. J Immunol 2004;172:2001-2005.
41. Kloss M, Decker P, Baltz KM et al. Interaction of monocytes with NK cells upon Tolllike receptor-induced expression of the NKG2D ligand MICA. J Immunol 2008;181: 6711-6719.
42. Nedvetzki S, Sowinski S, Eagle RA et al. Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood 2007;109: 3776-3785.
43. He W, Liu Q, Wang L et al. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007;44:2850-2859.
44. Huang B, Zhao J, Li H et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005;65: 5009-5014.
45. Szczepanski MJ, Czystowska M, Szajnik M et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009;69:3105-3113.
46. Selmani Z, Naji A, Zidi I et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD41CD25high FOXP31 regulatory T cells. Stem Cells 2008;26:212-222.